المؤلفون: Patel AA; Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, IL., Yoon JJ; Division of Hematologic Malignancies, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA., Johnston H; Department of Medicine, Internal Medicine Residency, University of Chicago, Chicago, IL., Davidson MB; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Shallis RM; Department of Internal Medicine, Section of Hematology, Yale School of Medicine and Yale Cancer Center, New Haven, CT., Chen EC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Burkart M; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC., Oh TS; Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL., Iyer SG; Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY., Madarang E; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Muthiah C; Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI., Gross I; University of Chicago Comprehensive Cancer Center, Chicago, IL., Dean R; University of Chicago Comprehensive Cancer Center, Chicago, IL., Kassner J; Memorial Sloan Kettering Cancer Center, New York, NY., Viswabandya A; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Madero-Marroquin R; Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, IL., Rampal RK; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY., Guru Murthy GS; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI., Bradley T; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Abaza Y; Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL., Garcia JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Gupta V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Pettit KM; Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan Medical School, Michigan Medicine, Ann Arbor, MI., Cursio JF; Department of Public Health Sciences, University of Chicago, Chicago, IL., Odenike O; Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, IL.

المصدر: Blood advances [Blood Adv] 2024 Jul 09; Vol. 8 (13), pp. 3468-3477.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Myeloproliferative Disorders*/therapy , Myeloproliferative Disorders*/mortality , Myeloproliferative Disorders*/drug therapy, Humans ; Female ; Middle Aged ; Male ; Aged ; Adult ; Treatment Outcome ; Hematopoietic Stem Cell Transplantation ; Aged, 80 and over ; Blast Crisis/therapy ; Blast Crisis/mortality ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use

المؤلفون: Kaur A; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI., Venkatesan A; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI., Kandarpa M; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, MI., Talpaz M; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, MI., Raghavan M; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI.

المصدر: Blood advances [Blood Adv] 2024 Jul 09; Vol. 8 (13), pp. 3372-3387.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Calreticulin*/metabolism , Calreticulin*/genetics , Receptors, Thrombopoietin*/metabolism , Receptors, Thrombopoietin*/genetics , Myeloproliferative Disorders*/metabolism , Myeloproliferative Disorders*/genetics , Lysosomes*/metabolism , Mutation*, Humans ; Proteolysis ; TOR Serine-Threonine Kinases/metabolism ; Cell Proliferation

المؤلفون: Wolf D; Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.; Tyrolean Cancer Research Institute, Innsbruck, Austria., Pircher A; Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.; Tyrolean Cancer Research Institute, Innsbruck, Austria.

المصدر: Blood advances [Blood Adv] 2024 May 14; Vol. 8 (9), pp. 2310-2311.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Janus Kinase 2*/genetics , Janus Kinase 2*/metabolism , Myeloproliferative Disorders*/genetics , Myeloproliferative Disorders*/metabolism , Myeloproliferative Disorders*/drug therapy, Humans ; Mutation ; Molecular Targeted Therapy ; Animals

المؤلفون: Usart M; Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Hansen N; Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Stetka J; Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Almeida Fonseca T; Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Guy A; Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.; UMR1034, Inserm, Biology of Cardiovascular Diseases, University of Bordeaux, Pessac, France., Kimmerlin Q; Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Rai S; Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Hao-Shen H; Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Roux J; Bioinformatics core facility, Department of Biomedicine, University of Basel, Basel, Switzerland.; Swiss Institute of Bioinformatics, Basel, Switzerland., Dirnhofer S; Department of Pathology, University Hospital Basel, Basel, Switzerland., Skoda RC; Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.

المصدر: Blood advances [Blood Adv] 2024 May 14; Vol. 8 (9), pp. 2312-2325.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Myeloproliferative Disorders*/drug therapy , Myeloproliferative Disorders*/metabolism , Janus Kinase 2*/metabolism , Janus Kinase 2*/antagonists & inhibitors , Hematopoiesis*/drug effects , Glutaminase*/antagonists & inhibitors , Glutaminase*/metabolism , Benzeneacetamides*/pharmacology , Benzeneacetamides*/therapeutic use, Animals ; Mice ; Humans ; Mutation ; Pyrimidines/pharmacology ; Pyrimidines/therapeutic use

المؤلفون: Baranwal A; Division of Hematology, Mayo Clinic, Rochester, MN., Basmaci R; Division of Hematology, Mayo Clinic, Rochester, MN., He R; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Viswanatha D; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Greipp P; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Murthy HS; Division of Hematology, Mayo Clinic, Jacksonville, FL., Foran J; Division of Hematology, Mayo Clinic, Jacksonville, FL., Palmer J; Division of Hematology, Mayo Clinic, Phoenix, AZ., Hogan WJ; Division of Hematology, Mayo Clinic, Rochester, MN., Litzow MR; Division of Hematology, Mayo Clinic, Rochester, MN., Hefazi M; Division of Hematology, Mayo Clinic, Rochester, MN., Mangaonkar A; Division of Hematology, Mayo Clinic, Rochester, MN., Shah MV; Division of Hematology, Mayo Clinic, Rochester, MN., Al-Kali A; Division of Hematology, Mayo Clinic, Rochester, MN., Alkhateeb HB; Division of Hematology, Mayo Clinic, Rochester, MN.

المصدر: Blood advances [Blood Adv] 2024 Feb 13; Vol. 8 (3), pp. 562-570.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation* , Myeloproliferative Disorders*/genetics , Myeloproliferative Disorders*/therapy , Neoplasms*, Humans ; Stem Cell Transplantation ; Transplantation, Homologous ; WT1 Proteins/genetics

المؤلفون: Rai S; Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland., Zhang Y; Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland., Grockowiak E; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Hematology, University of Cambridge, Cambridge, United Kingdom.; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge, United Kingdom., Kimmerlin Q; Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland., Hansen N; Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland., Stoll CB; Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland., Usart M; Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland., Luque Paz D; University of Angers, Nantes Université, CHU Angers, INSERM, CNRS, CRCI2NA, Angers, France., Hao-Shen H; Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland., Zhu Y; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Hematology, University of Cambridge, Cambridge, United Kingdom.; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge, United Kingdom., Roux J; Department of Biomedicine, Bioinformatics core facility, University of Basel, Basel, Switzerland.; Swiss Institute of Bioinformatics, Basel, Switzerland., Bader MS; Division of Hematology, University Hospital Basel, Basel, Switzerland., Dirnhofer S; Department of Pathology, University Hospital Basel, Basel, Switzerland., Farady CJ; Novartis Institutes for BioMedical Research Forum 1, Basel, Switzerland., Schroeder T; Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland., Méndez-Ferrer S; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom.; Department of Hematology, University of Cambridge, Cambridge, United Kingdom.; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge, United Kingdom., Skoda RC; Department of Biomedicine, Experimental Hematology, University Hospital Basel, University of Basel, Basel, Switzerland.

المصدر: Blood advances [Blood Adv] 2024 Mar 12; Vol. 8 (5), pp. 1234-1249.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Myeloproliferative Disorders*/genetics, Animals ; Mice ; Animals, Genetically Modified ; Bone Marrow Transplantation ; Hematopoietic Stem Cells ; Interleukin-1beta

المؤلفون: Davidson MB; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Kennedy JA; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Capo-Chichi JM; Department of Clinical Laboratory Genetics, Laboratory Medicine Program, Toronto, ON, Canada., Shi Y; Biostatistics Department, University Health Network, Toronto, ON, Canada., Xu W; Biostatistics Department, University Health Network, Toronto, ON, Canada., Cheung V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Arruda A; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Bankar A; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Richard-Carpentier G; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Chan S; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Maze D; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Minden MD; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Schimmer AD; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Schuh AC; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Sibai H; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Yee K; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Tierens A; Department of Hematopathology, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada., Viswabandya A; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Gupta V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

المصدر: Blood advances [Blood Adv] 2024 Mar 12; Vol. 8 (5), pp. 1281-1294.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Myeloproliferative Disorders*/genetics, Humans ; Treatment Outcome ; Retrospective Studies ; Cytarabine/therapeutic use ; Daunorubicin

المؤلفون: Yu K; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Deuitch N; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Merguerian M; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.; Department of Pediatrics, Johns Hopkins University School of Medicine, Balltimore, MD., Cunningham L; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.; Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Davis J; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Bresciani E; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Diemer J; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Andrews E; Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Young A; NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Donovan F; Genomics Core, Division of Intramural Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Sood R; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Craft K; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Chong S; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Chandrasekharappa S; Genomics Core, Division of Intramural Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Mullikin J; NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Liu PP; Oncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.

المصدر: Blood advances [Blood Adv] 2024 Jan 23; Vol. 8 (2), pp. 497-511.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Acute*/genetics , Leukemia, Myeloid, Acute*/pathology , Myeloproliferative Disorders*/genetics , Hematologic Neoplasms*/genetics , Blood Platelet Disorders* , Blood Coagulation Disorders, Inherited*, Humans ; Aged ; Core Binding Factor Alpha 2 Subunit/genetics ; Genomics ; Germ Cells/pathology

SCR Disease Name: Platelet Disorder, Familial, with Associated Myeloid Malignancy

المؤلفون: Maierhofer A; Munich Leukemia Laboratory, Munich, Germany., Mehta N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY., Chisholm RA; Department of Biological Sciences, National University of Singapore, Singapore., Hutter S; Munich Leukemia Laboratory, Munich, Germany., Baer C; Munich Leukemia Laboratory, Munich, Germany., Nadarajah N; Munich Leukemia Laboratory, Munich, Germany., Pohlkamp C; Munich Leukemia Laboratory, Munich, Germany., Thompson ER; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Australia., James PA; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Kern W; Munich Leukemia Laboratory, Munich, Germany., Haferlach C; Munich Leukemia Laboratory, Munich, Germany., Meggendorfer M; Munich Leukemia Laboratory, Munich, Germany., Haferlach T; Munich Leukemia Laboratory, Munich, Germany., Blombery P; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Australia.; Torsten Haferlach Leukaemiediagnostik Stiftung, Munich, Germany.

المصدر: Blood advances [Blood Adv] 2023 Dec 12; Vol. 7 (23), pp. 7346-7357.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: Myelodysplastic Syndromes*/diagnosis , Myelodysplastic Syndromes*/genetics , Myeloproliferative Disorders*/genetics , Leukemia, Myeloid, Acute*/diagnosis , Leukemia, Myeloid, Acute*/genetics , Hematologic Neoplasms*/diagnosis , Hematologic Neoplasms*/genetics, Humans ; DEAD-box RNA Helicases/genetics ; Genomics

المؤلفون: Satty A; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Stieglitz E; Department of Pediatrics, Benioff Children's Hospitals, University of California San Francisco, San Francisco, CA., Kucine N; Department of Pediatrics, Weill Cornell Medicine, New York, NY.

المصدر: Hematology. American Society of Hematology. Education Program [Hematology Am Soc Hematol Educ Program] 2023 Dec 08; Vol. 2023 (1), pp. 37-42.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 100890099 Publication Model: Print Cited Medium: Internet ISSN: 1520-4383 (Electronic) Linking ISSN: 15204383 NLM ISO Abbreviation: Hematology Am Soc Hematol Educ Program Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelomonocytic, Juvenile*/diagnosis , Leukemia, Myelomonocytic, Juvenile*/genetics , Leukemia, Myelomonocytic, Juvenile*/therapy , Down Syndrome*/genetics , Myeloproliferative Disorders*, Infant ; Humans ; Child ; Child, Preschool ; Leukocytosis/diagnosis ; Leukocytosis/genetics ; Leukocytosis/therapy ; Mutation

SCR Disease Name: Myeloproliferative Syndrome, Transient